Latest News about NBIX
Recent news which mentions NBIX
   What Analysts Are Saying About Neurocrine Biosciences Stock
   
  December 20, 2024
  Tickers 
   NBIX
  
  
  From Benzinga
 
   Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
   
  
  
  December 16, 2024
  From Benzinga
 
   Screening For Black Friday Bargains In The Stock Market
   
  
  
  December 03, 2024
  From Benzinga
 
   AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
   
  
  
  November 12, 2024
  From Benzinga
 
   Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know
   
  October 04, 2024
  Tickers 
   NBIX
  
  
  From Benzinga
 
   "Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins
   
  
  
  September 30, 2024
  From Motley Fool
 
   Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint
   
  
  
  September 13, 2024
  From Benzinga
 
   Decoding 19 Analyst Evaluations For Neurocrine Biosciences
   
  September 09, 2024
  Tickers 
   NBIX
  
  
  From Benzinga
 
   Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
   
  
  
  September 08, 2024
  From Benzinga
 
   Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
   
  
  
  September 02, 2024
  From Benzinga
 
   Why Neurocrine Biosciences Stock Was Tumbling This Week
   
  August 30, 2024
  Tickers 
   NBIX
  
  
  From Motley Fool
 
   Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
   
  
  
  August 29, 2024
  From Benzinga
 From Benzinga
 
   Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
   
  
  
  August 28, 2024
  From Benzinga
 
   As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
   
  
  
  August 28, 2024
  From Benzinga
 
   US Stocks Mixed; JM Smucker Slashes Annual Guidance
   
  
  
  August 28, 2024
  From Benzinga
 
   Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
   
  
  
  August 27, 2024
  From Benzinga
 
   9 Health Care Stocks Whale Activity In Today's Session
   
  
  
  August 13, 2024
  From Benzinga
 From InvestorPlace
 Tickers 
   NBIX
  
  
  From InvestorPlace
 
   3 Red-Hot Biotech Rockets Blasting Off in 2024
   
  
  
  April 24, 2024
  From InvestorPlace
 
   Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
   
  
  
  April 23, 2024
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.